Related Experiment Video
Updated: Jul 31, 2026
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Adjunctive therapy with bromocriptine in Parkinson's disease
J A Temlett1, A Ming, M Saling
1Neurology Unit, Johannesburg Hospital.
Summary
Adding bromocriptine to levodopa treatment helped Parkinson's patients manage side effects. This approach reduced levodopa dosage by 30%, improving symptoms without worsening the disease stage.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease is a progressive neurodegenerative disorder.
- Chronic levodopa use can lead to adverse effects, complicating treatment.
- Managing levodopa-induced side effects is crucial for patient quality of life.
Purpose of the Study:
- To evaluate the efficacy and safety of adding bromocriptine to levodopa therapy in Parkinson's disease patients.
- To determine if bromocriptine can reduce levodopa dosage and associated side effects.
- To assess the impact on the clinical parkinsonian stage.
Main Methods:
- A study involving patients with moderately severe Parkinson's disease.
- Addition of bromocriptine (up to 26 mg daily) to existing levodopa regimens.
- Monitoring of levodopa dosage reduction, side effects, and clinical parkinsonian stage.
Main Results:
- Bromocriptine addition allowed an approximate 30% reduction in levodopa dose.
- Significant decrease in levodopa-related side effects was observed.
- Parkinsonian clinical stage was maintained or improved.
- Optimal effectiveness was achieved with bromocriptine doses up to 25-30 mg daily.
- Slow dose titration of bromocriptine minimized adverse reactions, which were typically transient.
Conclusions:
- Bromocriptine is a beneficial adjunct therapy for Parkinson's disease patients experiencing levodopa-induced adverse effects.
- This combination therapy allows for reduced levodopa dosage while maintaining or improving motor function.
- Careful dose titration of bromocriptine ensures good tolerability and minimizes side effects.
Related Concept Videos
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...